Peptris raises INR 70 crore Series A to advance AI-led drug discovery
Peptris has raised INR 70 crore ($7.7 million) in a Series A round to advance programs toward clinical readiness and expand its AI-led drug discovery pipeline over 24 months.
Peptris has raised INR 70 crore (USD 7.7 million) in a Series A funding round co-led by IAN Alpha Fund and Speciale Invest, with participation from Tenacity Ventures, BYT Ventures and other investors. The company said the fresh capital will be used over the next 24 months to advance existing programs toward clinical readiness, expand the discovery pipeline, and strengthen teams across biology, chemistry, data science and artificial intelligence.
Founded in 2019, Peptris develops artificial intelligence models that generate novel molecules and predict key drug development parameters. The company said its technology aims to reduce failures in early-stage drug development, where scientific uncertainty and high costs often prevent promising therapies from advancing.
Peptris said its platform has led to the discovery of Novel Chemical Entities (NCEs) and identified drug repurposing and rescue opportunities. By predicting efficacy, safety and other parameters early, the platform aims to enable faster decision-making and reduce time and cost in pre-clinical research.
The company focuses on therapeutic areas such as rare diseases, inflammation, oncology and women’s health. It operates a B2B model, partnering with pharmaceutical and biotechnology firms to license assets and co-develop programs targeting global markets.
Peptris said it plans to initiate multiple new NCE programs and repurpose shelved clinical-stage compounds to accelerate development timelines.